CRDF - NASDAQ
Cardiff Oncology, Inc.
$1.51
+7.5%Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
At a Glance
Live Snapshotcrdf
Selling, General and Administrative Expenses
Last Annual Value
14.22M
3-Year CAGR
3%
5-Year CAGR
12%
10-Year CAGR
%
Cardiff Oncology, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Cardiff Oncology, Inc. NASDAQ:CRDF | 14.22M | 2.9% | 3.7% | -4.7% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 15.21M | 3.0% | -5.7% | 8.9% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 12.41M | 5.3% | 10.2% | 11.3% | |
 PepGen Inc. NASDAQ:PEPG | 22.57M | 10.7% | 22.7% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 12.20M | 55.2% | N/A | N/A | |
 Alto Neuroscience, Inc. NYSE:ANRO | 20.75M | 40.3% | 40.8% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 36.20M | -4.9% | 1.7% | N/A | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 9.42M | 7.8% | 23.0% | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 56.01M | 39.5% | 5.4% | N/A | |
 Rani Therapeutics Holdings, Inc. NASDAQ:RANI | 19.74M | -9.3% | -6.6% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 68.80M | 60.8% | 53.6% | 28.1% |
Cardiff Oncology, Inc. Fair Value Envelope
Related Guides
Continue your CRDF research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.